Nitromed axes BiDil sales reps

Share this article:

Nitromed announced it plans to lay off a majority of its newly hired BiDil sales force by roughly 70 to 90 employees.

Nitromed doubled its sales force from 30 to 60 specialist reps during the second half of 2007 to boost BiDil. “However, with only modest improvement in sales, management concluded that it cannot sustain BiDil marketing efforts alone,” wrote Friedman, Billings, Ramsey & Co. analyst Robert Uhl in a recent note to investors. Nitromed now expects to file the NDA for BiDil XR with the FDA in 2010. Nitromed has hired an investment bank to explore strategic options, which could lead to sale of the company, Uhl wrote. 
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...